359 related articles for article (PubMed ID: 19074897)
1. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells.
Liu P; Li S; Gan L; Kao TP; Huang H
Cancer Res; 2008 Dec; 68(24):10290-9. PubMed ID: 19074897
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
Gan L; Chen S; Wang Y; Watahiki A; Bohrer L; Sun Z; Wang Y; Huang H
Cancer Res; 2009 Nov; 69(21):8386-94. PubMed ID: 19826044
[TBL] [Abstract][Full Text] [Related]
3. FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.
Bohrer LR; Liu P; Zhong J; Pan Y; Angstman J; Brand LJ; Dehm SM; Huang H
Prostate; 2013 Jul; 73(10):1017-27. PubMed ID: 23389878
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxo1 with androgen receptor.
Fan W; Yanase T; Morinaga H; Okabe T; Nomura M; Daitoku H; Fukamizu A; Kato S; Takayanagi R; Nawata H
J Biol Chem; 2007 Mar; 282(10):7329-38. PubMed ID: 17202144
[TBL] [Abstract][Full Text] [Related]
5. Modulation of androgen receptor by FOXA1 and FOXO1 factors in prostate cancer.
Zhao Y; Tindall DJ; Huang H
Int J Biol Sci; 2014; 10(6):614-9. PubMed ID: 24948874
[TBL] [Abstract][Full Text] [Related]
6. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
[TBL] [Abstract][Full Text] [Related]
7. FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment.
Ma Q; Fu W; Li P; Nicosia SV; Jenster G; Zhang X; Bai W
Mol Endocrinol; 2009 Feb; 23(2):213-25. PubMed ID: 19074551
[TBL] [Abstract][Full Text] [Related]
8. Androgen-dependent regulation of Her-2/neu in prostate cancer cells.
Berger R; Lin DI; Nieto M; Sicinska E; Garraway LA; Adams H; Signoretti S; Hahn WC; Loda M
Cancer Res; 2006 Jun; 66(11):5723-8. PubMed ID: 16740710
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Liu Y; Majumder S; McCall W; Sartor CI; Mohler JL; Gregory CW; Earp HS; Whang YE
Cancer Res; 2005 Apr; 65(8):3404-9. PubMed ID: 15833875
[TBL] [Abstract][Full Text] [Related]
10. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
Sadar MD; Gleave ME
Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
[TBL] [Abstract][Full Text] [Related]
11. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
Lyons LS; Burnstein KL
Mol Endocrinol; 2006 May; 20(5):1061-72. PubMed ID: 16384856
[TBL] [Abstract][Full Text] [Related]
12. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion.
Zhang H; Pan Y; Zheng L; Choe C; Lindgren B; Jensen ED; Westendorf JJ; Cheng L; Huang H
Cancer Res; 2011 May; 71(9):3257-67. PubMed ID: 21505104
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.
Yuan X; Li T; Wang H; Zhang T; Barua M; Borgesi RA; Bubley GJ; Lu ML; Balk SP
Am J Pathol; 2006 Aug; 169(2):682-96. PubMed ID: 16877366
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
[TBL] [Abstract][Full Text] [Related]
15. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.
Welsbie DS; Xu J; Chen Y; Borsu L; Scher HI; Rosen N; Sawyers CL
Cancer Res; 2009 Feb; 69(3):958-66. PubMed ID: 19176386
[TBL] [Abstract][Full Text] [Related]
17. 14-3-3 sigma increases the transcriptional activity of the androgen receptor in the absence of androgens.
Quayle SN; Sadar MD
Cancer Lett; 2007 Aug; 254(1):137-45. PubMed ID: 17433535
[TBL] [Abstract][Full Text] [Related]
18. Sterol regulatory element-binding protein-1c represses the transactivation of androgen receptor and androgen-dependent growth of prostatic cells.
Suh JH; Gong EY; Kim JB; Lee IK; Choi HS; Lee K
Mol Cancer Res; 2008 Feb; 6(2):314-24. PubMed ID: 18245227
[TBL] [Abstract][Full Text] [Related]
19. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
20. Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells.
Dai JL; Maiorino CA; Gkonos PJ; Burnstein KL
Steroids; 1996 Sep; 61(9):531-9. PubMed ID: 8883219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
